Scipio bioscience announces its Series A fund raising
A total of €6.0m has been obtained from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck. The initial shareholders Seventure Partners’ Quadrivum I (Paris, France) and High-Tech Gründerfonds (Bonn, Germany) participated in the capital increase, alongside additional investors Financière Arbevel (Paris, France) and Investiere Venture Capital (Zürich, Switzerland). Read the full press release in pdf here.
Paris, 25 February 2020 – Scipio bioscience, a Paris-based biotechnology company, developing a new generation
of single-cell sequencing solutions, announces today that it has secured a €6.0 M Series A financing from an
international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck.
The initialshareholders Seventure Partners’ Quadrivum I (Paris, France) and High-Tech Gründerfonds(Bonn, Germany)
participated in the capital increase, alongside additional investors Financière Arbevel (Paris, France) and investiere
“There is a substantial unmet need for cost-effective single-cell sequencing methods. The availability of such methods
will drive single-cell market growth globally, both in the basic and clinical research fields. Scipio bioscience is pioneering
affordable single-cell sample preparation for sequencing. We fully support the team to deliver a much-needed solution
based on their disruptive technology and to grow Scipio bioscience into a major player in single-cell biology” says
Arnaud Autret, Investment Principal at M Ventures.
Philippe Tramoy, Partner at the Quadrivium 1 seed capital fund at Seventure Partners, adds: “We are thrilled that our
seed investment in Scipio’s truly deep tech project was crucial to turn its disruptive technology into a potential game
changer. We look forward to getting to the next phases of development. ”
Prof Stuart Edelstein, President, says: “We are convinced that our user-friendly kit, requiring no specific equipment and
accessible for any benchtop, will enable thousands of additional scientists to perform single-cell RNA-sequencing. This
availability will change the way biological questions are addressed and ultimately benefit both basic research and
clinical applications. We are delighted to initiate collaborations for beta-testing of our kit, initially with ICM (Brain &
Spine Institute, Paris, France) laboratories, as the interactions so far with its world-class teams and cutting-edge core
facilities have been extremely fruitful. Our goal is to extend collaborations to leading European research institutes.”
The €6.0 M Series A funding will fuel the final development of its single-cell RNA-sequencing kit, as well as marketing
and business development efforts to prepare for commercial launch in 2022.